Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura M Güdemann

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Wellcome Open Research|October 10, 2025
Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataLaura M Güdemann, John M Dennis, Andrew P McGovern, et al.
The Lancet Regional Health. Europe|December 16, 2025
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort studyLaura M Güdemann, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|June 18, 2026
To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover TrialLaura M Güdemann, Catherine Angwin, Rury R Holman, et al.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Wellcome Open Research|October 10, 2025
Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataLaura M Güdemann, John M Dennis, Andrew P McGovern, et al.
The Lancet Regional Health. Europe|December 16, 2025
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort studyLaura M Güdemann, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|June 18, 2026
To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover TrialLaura M Güdemann, Catherine Angwin, Rury R Holman, et al.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Pageof 1